This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://localhost/temp/predkladatel/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/ontology/domain/vavai/
n12http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F09%3A3950%21RIV10-MSM-11110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F09%3A3950%21RIV10-MSM-11110___
rdf:type
n16:Vysledek skos:Concept
dcterms:description
The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study has prompted the investigation of whether natalizumab can increase the proportion of patients with relapsing-remitting multiple sclerosis who do not have disease activity. The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study has prompted the investigation of whether natalizumab can increase the proportion of patients with relapsing-remitting multiple sclerosis who do not have disease activity.
dcterms:title
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
skos:prefLabel
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
skos:notation
RIV/00216208:11110/09:3950!RIV10-MSM-11110___
n3:aktivita
n14:Z
n3:aktivity
Z(MSM0021620849)
n3:cisloPeriodika
3
n3:dodaniDat
n7:2010
n3:domaciTvurceVysledku
n13:8895465
n3:druhVysledku
n11:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
312186
n3:idVysledku
RIV/00216208:11110/09:3950
n3:jazykVysledku
n4:eng
n3:klicovaSlova
Placebo-controlled trial; double-blind; rheumatoid-arthritis; multicenter; disability; methotrexate
n3:klicoveSlovo
n8:double-blind n8:multicenter n8:methotrexate n8:Placebo-controlled%20trial n8:disability n8:rheumatoid-arthritis
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[50870E4366AC]
n3:nazevZdroje
Lancet Neurology
n3:obor
n10:FH
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
13
n3:rokUplatneniVysledku
n7:2009
n3:svazekPeriodika
8
n3:tvurceVysledku
Bates, D. Havrdová, Eva Kim, R. Lublin, FD Hyde, R. Galetta, S. Hutchinson, M. Giovannoni, G. Polman, C. H. Phillips, JT O'Connor, PW Pace, A. Stefoski, D.
n3:wos
000263711200015
n3:zamer
n12:MSM0021620849
s:issn
1474-4422
s:numberOfPages
7
n9:organizacniJednotka
11110